Please login to the form below

Not currently logged in

Savient appoints Louis Ferrari to CEO as job cuts announced

Gout drug specialist says 35 per cent of workforce will go

Louis Ferrari - SavientSavient Pharmaceuticals has promoted executive VP, president North American commercial operations Louis Ferrari (pictured) to the role of president and CEO the same day it announced it plans to cut 35 per cent of its workforce.

Taking over immediately from interim CEO David Norton, Ferrari will lead the US biopharma's plans to reduce its field force to consist of 35 key account managers and three regional business directors by September, 2012.

It is expected these cuts will generate about $56m in annual operating expense savings by 2013, although Savient will take a hit of $4.7m in restructuring and employee severance charges.

“On behalf of the entire board and management team, we sincerely regret having to make the difficult decision to reduce our workforce and want to thank the affected employees for their contributions," said the company's chair Stephen Jaeger.

"However, given the current environment, these actions are necessary to align Savient's costs with the market to best position the Company going forward."

New CEO Ferrari has been at Savient since 2011, and has already played a major role in the company's ongoing commercialisation of gout drug Krystexxa (pegloticase).

He has over 30 years of experience in the pharmaceutical industry, including product launches, product development, international marketing, sales management, sales training and clinical trials.

Prior to joining Savient, Ferrari served at Johnson & Johnson (J&J) as VP of oncology and nephrology, sales and marketing. He has also served on the management board of both Ortho Biotech and Centocor.

He said: "I am honoured to be given the opportunity to take on the role of President and CEO of Savient during this critical time in the company's history.”

10th July 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...